Resistant thrombocytopenia in an HIV and hepatitis C patient: treatment response with novel agent eltrombopag

  • Rajakrishnan Vijayakrishnan | vrajakrishnan@gmail.com
  • Sourbha Dani
  • Aparna Ramasubramanian
  • Rekha Nair
  • Tony M. Samaha

Abstract

HIV-associated thrombocytopenia is a dis- ease which can be recurrent to standard therapy which includes highly active antiretroviral therapy (HAART) therapy, steroids and immunoglobulin. We report a patient with HIV and hepatitis C who presented with resistant thrombocytopenia. Treatment with Eltrombopag – a thrombopoeitin receptor agonist showed initial good response with recurrence of thrombocytopenia. This novel agent could be considered as a treatment option prior to splenectomy and may be useful as a tempo- rizing measure.

Downloads

Download data is not yet available.
Published
2011-03-29
Section
Case Reports
Keywords:
Thrombocytopenia, Eltrombopag, Human Immunodeficiency Virus, Hepatitis C, Hematologic Diseases
Statistics
Abstract views: 1440

PDF: 99
HTML: 90
Share it

PlumX Metrics

PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.

How to Cite
Vijayakrishnan, R., Dani, S., Ramasubramanian, A., Nair, R., & Samaha, T. (2011). Resistant thrombocytopenia in an HIV and hepatitis C patient: treatment response with novel agent eltrombopag. Clinics and Practice, 1(1), e5. https://doi.org/10.4081/cp.2011.e5